Recent studies employing the use of biologics have identified the inhibition of interleukin-4 and interleukin-13 as a pathway that can be targeted to reduce COPD symptoms in patients presenting a high eosinophil count [129,134]. Here, IL13 is linked to chronic obstructive pulmonary disease.